home / stock / ganx / ganx news

GANX News and Press, Gain Therapeutics Inc. From 03/15/24

Stock Information
Company Name: Gain Therapeutics Inc.
Stock Symbol: GANX
Market: NASDAQ
Website: gaintherapeutics.com
Menu
GANX GANX Quote GANX Short GANX News GANX Articles GANX Message Board
Get GANX Alerts

News, Short Squeeze, Breakout and More Instantly...
GANX - Gain Therapeutics to Present at Public Ventures Discovery Day

BETHESDA, Md., March 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announ...
GANX - Gain Therapeutics Presents Data at the AD/PD(TM) 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease

BETHESDA, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announ...

GANX - Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the...

GANX - Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight

BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a 2024 Research & Development upd...
GANX - UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

BETHESDA, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces preclinical data demonstrating that its clinical-stage GC...

GANX - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

BETHESDA, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces preclinical data demonstrating that its clinical-stage GC...

GANX - Gain Therapeutics' CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

BETHESDA, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain,” or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today releases the following letter to stockholders...
GANX - Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

2024-01-12 18:49:40 ET Summary Gain Therapeutics' drug candidate GT-02287 targets GCase and lysosomal dysfunction, potentially succeeding where others may fail. The company's AI-driven drug discovery engine has generated several targets across different diseases. GT-02287 is c...

GANX - Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium(TM) 2024

BETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announc...

GANX - Doubling Down On Gain Therapeutics

2023-12-22 17:56:28 ET Summary The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success usi...
Previous 10 Next 10